Issues in the Ttreatment of neurological conditions caused by reactivation of varicella zoster virus (VZV)

Kennedy, P. G.E. (2016) Issues in the Ttreatment of neurological conditions caused by reactivation of varicella zoster virus (VZV). Neurotherapeutics, 13(3), pp. 509-513. (doi: 10.1007/s13311-016-0430-x) (PMID:27032406)

Full text not currently available from Enlighten.

Abstract

Varicella zoster virus (VZV) is a ubiquitous neurotropic human herpesvirus. Primary infection usually causes varicella (chicken pox), after which virus becomes latent in ganglia along the entire neuraxis. Decades later, virus reactivates to produce herpes zoster (shingles), a painful dermatomally distributed vesicular eruption. Zoster may be further complicated by postherpetic neuralgia, VZV vasculopathy, myelitis, and segmental motor weakness. VZV reactivation has also been associated with giant cell arteritis. This overview discusses treatment of various conditions that often require both corticosteroids and antiviral drugs. Treatment for VZV-associated disease is often based on case reports and small studies rather than large-scale clinical trials. Issues that require resolution include the optimal duration of such combined therapy, more effective treatment for postherpetic neuralgia, whether some treatments should be given orally or intravenously, the widening spectrum of zoster sine herpete, and the role of antiviral therapy in giant cell arteritis.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Kennedy, Professor Peter
Authors: Kennedy, P. G.E.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Neurotherapeutics
Publisher:Springer US
ISSN:1933-7213
ISSN (Online):1878-7479
Published Online:31 March 2016

University Staff: Request a correction | Enlighten Editors: Update this record